Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab for Crohn's disease in Chinese real-world practice
ChiCTR2000034861Phase 4Recruiting
- Sponsor
- Xijing Hospital
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ustekinumab in Crohn's disease, sponsored by Xijing Hospital. Primary endpoints: Clinical response rate at week 8, Clinical remission rate at week 8 and 2 more. Started Jul 2020; status: recruiting.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2000034861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034861.